Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review
CONCLUSION: Evolving research on pembrolizumab allows a deeper clinical understanding, despite challenges as variable patient responses. Pembrolizumab has emerged as a pivotal breakthrough in cancer treatment, improving patient outcomes and safety.PMID:38658461 | DOI:10.1007/s12094-024-03491-8 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 24, 2024 Category: Cancer & Oncology Authors: V ítor Silva Cristiano Matos Source Type: research
Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review
CONCLUSION: Evolving research on pembrolizumab allows a deeper clinical understanding, despite challenges as variable patient responses. Pembrolizumab has emerged as a pivotal breakthrough in cancer treatment, improving patient outcomes and safety.PMID:38658461 | DOI:10.1007/s12094-024-03491-8 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 24, 2024 Category: Cancer & Oncology Authors: V ítor Silva Cristiano Matos Source Type: research
Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review
CONCLUSION: Evolving research on pembrolizumab allows a deeper clinical understanding, despite challenges as variable patient responses. Pembrolizumab has emerged as a pivotal breakthrough in cancer treatment, improving patient outcomes and safety.PMID:38658461 | DOI:10.1007/s12094-024-03491-8 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 24, 2024 Category: Cancer & Oncology Authors: V ítor Silva Cristiano Matos Source Type: research
Recent updates in the therapeutic uses of Pembrolizumab: a brief narrative review
CONCLUSION: Evolving research on pembrolizumab allows a deeper clinical understanding, despite challenges as variable patient responses. Pembrolizumab has emerged as a pivotal breakthrough in cancer treatment, improving patient outcomes and safety.PMID:38658461 | DOI:10.1007/s12094-024-03491-8 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - April 24, 2024 Category: Cancer & Oncology Authors: V ítor Silva Cristiano Matos Source Type: research
Trends and costs of minimally invasive surgery for kidney cancer in the US: A population-based study
To analyze temporal trends and costs associated with the use of minimally invasive surgery (MIS) for kidney cancer in the US over the past decade. To examine the impact of social determinants of health (SDOH) on perioperative outcomes. (Source: Urology)
Source: Urology - April 24, 2024 Category: Urology & Nephrology Authors: Francesco Ditonno, Antonio Franco, Celeste Manfredi, Morgan R. Sturgis, Carol L. Feng, Daniel F. Roadman, Spencer M. Mossak, Eugenio Bologna, Leslie C. Licari, Cosimo De Nunzio, Nicholas J. Corsi, Craig Rogers, Firas Abdollah, Alessandro Antonelli, Edward Source Type: research
Increased level of serum leucine-rich-alpha-2-glycoprotein 1 in patients with clear cell renal cell carcinoma
Currently, no useful serum markers exist for clear cell renal cell carcinoma (ccRCC), making early detection challenging as diagnosis relies solely on imaging tests. Radiation exposure is also a concern due to... (Source: BMC Urology)
Source: BMC Urology - April 24, 2024 Category: Urology & Nephrology Authors: Shotaro Nakanishi, Masato Goya, Tetsuji Suda, Tomoko Yonamine, Ai Sugawa and Seiichi Saito Tags: Research Source Type: research
Genes, Vol. 15, Pages 537: CD44 Expression in Clear Cell Renal Cell Carcinoma (ccRCC) Correlates with Tumor Grade and Patient Survival and Is Affected by Gene Methylation
rmpetzoglou
Clear cell RCC (ccRCC) represents the most common type of kidney cancer, with surgery being the only potential curative treatment. Almost one-third of ccRCC patients relapse either locally or as cases of distant metastases. Several biomarkers have been employed in order to separate ccRCC patients with better prognosis or to predict treatment outcomes, with limited results. CD44 is a membrane glycoprotein with multiple roles in normal development but also cancer. Recently, the CD44 standard isoform has been implicated in tumor progression and the metastasis cascade through microenvironment interactions. Here...
Source: Genes - April 24, 2024 Category: Genetics & Stem Cells Authors: Anastasios D. Papanastasiou Stavros Peroukidis Chaido Sirinian Elisavet Arkoumani Dimitrios Chaniotis Adamantia Zizi-Sermpetzoglou Tags: Brief Report Source Type: research
CDCA5-EEF1A1 interaction promotes progression of clear cell renal cell carcinoma by regulating mTOR signaling
Cell division cycle associated 5 (CDCA5) plays ontogenetic role in various human cancers. However, its specific function and regulatory mechanism in ccRCC remain uncertain. (Source: Cancer Cell International)
Source: Cancer Cell International - April 24, 2024 Category: Cancer & Oncology Authors: Xun Wang, An Shi, Jie Liu, Wen Kong, Yiran Huang, Wei Xue, Fan Yang and Jiwei Huang Tags: Research Source Type: research
A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2 α in Patients with Advanced Clear Cell Renal Cell Carcinoma
CONCLUSIONS: ARO-HIF2 downregulated HIF2α in advanced ccRCC-inhibiting tumor growth in a subset of subjects. Further development was hampered by off-target neurotoxicity and low response rate. This study provides proof of concept that siRNA can target tumors in a specific manner.PMID:38652038 | DOI:10.1158/1078-0432.CCR-23-3029 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 23, 2024 Category: Cancer & Oncology Authors: James Brugarolas Gregory Obara Kathryn E Beckermann Brian Rini Elaine T Lam James Hamilton Thomas Schluep Min Yi So Wong Zhongping Lily Mao Erick Gamelin Nizar M Tannir Source Type: research
A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2 α in Patients with Advanced Clear Cell Renal Cell Carcinoma
CONCLUSIONS: ARO-HIF2 downregulated HIF2α in advanced ccRCC-inhibiting tumor growth in a subset of subjects. Further development was hampered by off-target neurotoxicity and low response rate. This study provides proof of concept that siRNA can target tumors in a specific manner.PMID:38652038 | DOI:10.1158/1078-0432.CCR-23-3029 (Source: Cancer Control)
Source: Cancer Control - April 23, 2024 Category: Cancer & Oncology Authors: James Brugarolas Gregory Obara Kathryn E Beckermann Brian Rini Elaine T Lam James Hamilton Thomas Schluep Min Yi So Wong Zhongping Lily Mao Erick Gamelin Nizar M Tannir Source Type: research
Oncological results of repeat partial nephrectomy in patients with recurrence after nephron-sparing procedures
CONCLUSION: Repeat partial nephrectomy for local recurrence of kidney cancer leads to an increase in overall survival compared to radical nephrectomy, in the absence of significant differences in cancer-specific and relapse-free survival.PMID:38650411 (Source: Cancer Control)
Source: Cancer Control - April 23, 2024 Category: Cancer & Oncology Authors: B Matveev V K Zhumabaev N I Komarov M V Klimov A S Stilidi I Source Type: research
Comprehensive bioinformatics analysis of KIF20A as a prognosis biomarker for clear cell renal cell carcinoma
Cell Mol Biol (Noisy-le-grand). 2024 Mar 31;70(3):116-124. doi: 10.14715/cmb/2024.70.3.17.ABSTRACTIt has been shown that kinesin family member 20A (KIF20A) is involved in the development of several cancers. However, research on clear cell renal cell carcinoma (ccRCC) and KIF20A is still exploratory. The current research was carried out to determine whether KIF20A expression has any prognosis value in ccRCC. Data were downloaded from The Cancer Genome Atlas (TCGA) database to validate the KIF20A mRNA expression and to perform clinicopathological analysis. Receiver operating characteristic (ROC) curves were used in evaluatin...
Source: Cellular and Molecular Biology - April 23, 2024 Category: Molecular Biology Authors: Cankun Xie Wingkeung Yiu Yijiang Mo Source Type: research
Network analysis of histopathological image features and genomics data improving prognosis performance in clear cell renal cell carcinoma
CONCLUSION: This study developed a histopathological-genetic-related nomogram by combining histopathological features and clinical predictors, providing a more comprehensive prognostic assessment for clear cell renal cell carcinoma patients.PMID:38653593 | DOI:10.1016/j.urolonc.2024.03.016 (Source: Urologic Oncology)
Source: Urologic Oncology - April 23, 2024 Category: Urology & Nephrology Authors: Jianrui Ji Yunsong Liu Yongxing Bao Yu Men Zhouguang Hui Source Type: research
Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma
CONCLUSION: The SFI can be potentially utilized as an effective predictive and prognostic biomarker for first-line ICI combination therapy for advanced RCC.PMID:38653590 | DOI:10.1016/j.urolonc.2024.04.008 (Source: Urologic Oncology)
Source: Urologic Oncology - April 23, 2024 Category: Urology & Nephrology Authors: Hiroki Ishihara Koichi Nishimura Takashi Ikeda Hironori Fukuda Kazuhiko Yoshida Junpei Iizuka Tsunenori Kondo Toshio Takagi Source Type: research
The β3-AR agonist BRL37344 ameliorates the main symptoms of X-linked nephrogenic diabetes insipidus in the mouse model of the disease
J Cell Mol Med. 2024 Apr;28(8):e18301. doi: 10.1111/jcmm.18301.ABSTRACTX-linked nephrogenic diabetes insipidus (X-NDI) is a rare congenital disease caused by inactivating mutations of the vasopressin type-2 receptor (AVPR2), characterized by impaired renal concentrating ability, dramatic polyuria, polydipsia and risk of dehydration. The disease, which still lacks a cure, could benefit from the pharmacologic stimulation of other GPCRs, activating the cAMP-intracellular pathway in the kidney cells expressing the AVPR2. On the basis of our previous studies, we here hypothesized that the β3-adrenergic receptor could be such a...
Source: J Cell Mol Med - April 23, 2024 Category: Molecular Biology Authors: Serena Milano Ilenia Saponara Andrea Gerbino Monica Carmosino Maria Svelto Giuseppe Procino Source Type: research
